Resmed

ResMed divested MatrixCare (software business serving aged care) for US$490 million (~US$700m AUD), a ~33% haircut from the US$750m purchase price in 2018. Divestment signals portfolio rationalization and focus on core sleep health franchise.

Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in the sector.

curated · 2026-07-15 · context →

ResMed to sell MatrixCare business to Frazier Healthcare Partners

Leadership read: Selling MatrixCare removes ResMed's largest software-as-a-service business — a long-term care and post-acute EHR platform — from its operating portfolio. That is a material portfolio commitment, not a trim. MatrixCare was the anchor of ResMed's Software-as-a-Service segment, which the company had built through acquisition over several years as a hedge against hardware-cycle exposure. Divesting it to Frazier Healthcare Partners signals that ResMed is recentralizing around its core sleep and respiratory device business, accepting concentrated hardware-and-services revenue in exchange for a cleaner operating model. The strategic cost is real: the company sheds recurring software revenue and the patient-data adjacency that made post-acute EHR strategically attractive in the first place. This is one of twelve M&A signals we have tracked across sectors in the last 90 days, and the healthcare-adjacent subset — including Coral Connect's acquisition of AdvisorWoRx — reflects a consistent pattern: PE firms absorbing specialized vertical-software businesses that larger strategics are rationalizing out of diversified portfolios. The shape is recognizable: acquirer is a healthcare-specialist fund; the asset has embedded workflow relationships that compound slowly rather than growing through product-led velocity. Companies at this stage of portfolio contraction — shedding a vertical-software unit to refocus on medtech core — face concentrated demand for commercial leadership that can defend device-side margins without the cross-sell leverage a software platform previously provided, alongside product and clinical-data leadership that can rebuild software optionality natively rather than through acquisition.

curated · 2026-07-07 · context →

ResMed partnered with Oura (smart ring manufacturer) in May 2026 to connect Oura Ring's breathing disturbance metrics with ResMed's clinical education resources and virtual sleep care pathways. The partnership aims to drive patient referrals to sleep clinics by identifying undiagnosed obstructive sleep apnea through longitudinal wearable data.

Leadership read: Alliances like this can broaden the sector commercial leadership bench strength.

curated · 2026-07-01 · context →

Resmed partnered with Oura to connect wearable sleep data (Oura Ring) with Resmed's clinical care pathways and sleep health resources. US-focused initiative to guide users with nighttime breathing disturbances toward clinical evaluation for sleep disorders including obstructive sleep apnea.

Leadership read: Alliances like this can broaden the sector commercial leadership bench strength.

curated · 2026-05-26 · context →

ResMed launches AirConnect Dx in the UK to help NHS sleep services reduce diagnostic backlogs

Leadership read: Product momentum tends to widen the sector product and commercial leadership bench strength.

curated · 2026-05-21 · context →

CFO Brett Sandercock retiring May 4, 2026, replaced by Aaron Bloomer after comprehensive search

Leadership read: Leadership transitions often precede broader the sector bench-strengthening over the next two quarters.

curated · 2026-04-30 · context →